Contineum Therapeutics Past Earnings Performance
Past criteria checks 0/6
Contineum Therapeutics has been growing earnings at an average annual rate of 97.4%, while the Pharmaceuticals industry saw earnings growing at 0.03% annually. Revenues have been growing at an average rate of 203.3% per year.
Key information
97.4%
Earnings growth rate
97.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 203.3% |
| Return on equity | 16.3% |
| Net Margin | -0.9% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
No updates
Revenue & Expenses Breakdown
How Contineum Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 50 | 0 | 8 | 31 |
| 31 Dec 23 | 50 | 3 | 7 | 27 |
| 30 Sep 23 | 50 | -3 | 6 | 24 |
| 31 Dec 22 | 0 | -24 | 7 | 16 |
Quality Earnings: CTNM is currently unprofitable.
Growing Profit Margin: CTNM is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if CTNM's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare CTNM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CTNM is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (15.5%).
Return on Equity
High ROE: CTNM has a negative Return on Equity (16.35%), as it is currently unprofitable.